Hence, the effect of cisplatin on Tip60 expression, SRPK1 acetylation and pre-mRNA splicing preference as proposed in the putative model (Supplementary Fig. 18) may exhibit tissue specificity, and even heterogeneity within breast tumours as suggested by HCC70 responding to cisplatin differently from the other breast cancer cell lines tested regarding SRPK1 acetylation (Fig. 2i; Supplementary Fig. 15a). Here, KAT5 is linked to breast carcinoma.